Skip to content

Prospective Clinical Validation of the Efficacy of an Artificial Intelligence-Assisted Ultrasound System in Differentiating Benign and Malignant Breast Nodules: A Single-Center Observational Study

Prospective Clinical Validation of the Efficacy of an Artificial Intelligence-Assisted Ultrasound System in Differentiating Benign and Malignant Breast Nodules: A Single-Center Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600130575
Enrollment
Unknown
Registered
2026-08-21
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign breast nodule

Interventions

Index test:Diagnostic results from AI breast ultrasound screening software

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75, female (male breast cancer cases are rare, can be included at discretion but must be marked separately); 2. Need to undergo breast ultrasound (dynamic scanning and static image capture), examination site is both breasts; 3. After the exam, should be able to obtain complete dynamic ultrasound images (continuous scan video) and static ultrasound images (at least 3 key planes: transverse, longitudinal, and oblique), meeting AI software analysis requirements; 4. Willing to participate in this study, sign informed consent, and able to cooperate with follow-up and gold standard verification; 5. No severe liver or kidney dysfunction, mental illness, coagulation disorders, or other basic diseases that may affect the study; 6. Have not participated in other similar breast AI-related clinical studies.

Exclusion criteria

Exclusion criteria: 1. Poor quality of breast ultrasound images (blurry, severe artifacts, incomplete sections), which cannot meet the AI software analysis requirements; 2. History of breast surgery, radiotherapy/chemotherapy, or breast implant, affecting ultrasound image interpretation; 3. Already diagnosed with breast cancer and has received surgery, radiotherapy, chemotherapy, or other treatments; 4. Pregnant or breastfeeding women (breast tissue congestion and edema affecting imaging features); 5. Refuses to sign the informed consent form or cannot cooperate with follow-up or gold-standard verification; 6. Has other malignant tumors, with an expected survival of less than 6 months.

Design outcomes

Primary

MeasureTime frame
Accuracy of identifying breast tumors, benign or malignant;

Secondary

MeasureTime frame
the independent diagnostic results of ultrasound physicians with different professional titles/levels (junior, intermediate, and senior) versus the real-time on-device analysis results of the AI sof;examination and diagnostic time, System Usability Scale (SUS) scores for the AI software, and compatibility/operational records on GE ultrasound equipment.;

Countries

China

Contacts

Public ContactSun Desheng

Peking University Shenzhen Hospital

szdssun@163.com+86 13510331808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026